Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Seres Therapeutics Inc (NQ: MCRB )

3.630 +0.200 (+5.83%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 1, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,622,424
Open 3.340
Bid (Size) 3.530 (10)
Ask (Size) 3.920 (1)
Prev. Close 3.430
Today's Range 3.340 - 3.750
52wk Range 2.500 - 22.94
Shares Outstanding 92,230,428
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
From Seres Therapeutics, Inc.
Via Business Wire

Performance

YTD
-58.94%
-58.94%
1 Month
+13.79%
+13.79%
3 Month
-52.36%
-52.36%
6 Month
-58.94%
-58.94%
1 Year
-82.85%
-82.85%

More News

Read More
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug
Via Benzinga
Recap: Seres Therapeutics Q1 Earnings
Via Benzinga
Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis
Via Benzinga
79 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Earnings Scheduled For March 1, 2022
Via Benzinga
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints
Via Benzinga
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
Preview: Seres Therapeutics's Earnings
Via Benzinga
How To Attend Seres Therapeutics Q1 2022 Earnings Conference Call
Via Benzinga
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
From Seres Therapeutics, Inc.
Via Business Wire
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Seres Therapeutics' SER-155 Reduces Infection, GvHD In Animal Study
Via Benzinga
Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
Seres Therapeutics Earnings Perspective: Return On Capital Employed
Via Benzinga
Seres Therapeutics: Q4 Earnings Insights
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.